Surmodics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US8688731004
USD
42.98
0.15 (0.35%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Surmodics, Inc. stock-summary
stock-summary
Surmodics, Inc.
Pharmaceuticals & Biotechnology
Surmodics, Inc. is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company's Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device. The Company's In Vitro Diagnostics segment manufactures or sells components for in vitro diagnostic immunoassay and molecular tests. The In Vitro Diagnostics segment manufactures and sells surface coatings to the diagnostic, biomedical research and life science markets. In Vitro Diagnostics segment offers protein stabilization reagents, substrates, antigens and surface coatings.
Company Coordinates stock-summary
Company Details
9924 W 74th St , EDEN PRAIRIE MN : 55344-3523
stock-summary
Tel: 1 952 5007000
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 47 Schemes (24.8%)

Foreign Institutions

Held by 68 Foreign Institutions (23.58%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Ms. Susan Knight
Non-Executive Independent Chairman of the Board
Mr. Gary Maharaj
President, Chief Executive Officer, Director
Mr. Jose Bedoya
Independent Director
Dr. David Dantzker
Independent Director
Ms. Lisa Heine
Independent Director
Mr. Ronald Kalich
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
30 Million
(Quarterly Results - Jun 2025)
Net Profit:
-5 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 471 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.02

stock-summary
Return on Equity

-5.99%

stock-summary
Price to Book

4.23